News - Illumina


Current filters:


Popular Filters

Next generation sequencing market expected to grow to $2.7 billion by 2017


The next generation sequencing (NGS) market has been forecast to increase at a compound annual growth…

BiotechnologyEuropeGeneticsIlluminaMarkets & MarketingNorth America

Illumina acquires UK's BlueGnome


US developer, manufacturer and marketer of life science tools and integrated systems for the analysis…

BlueGnomeIlluminaMergers & AcquisitionsPharmaceutical

Roche will not extend its tender offer for Illumina


In view of the apparent re-election of the incumbent directors of Illumina (Nasdaq: ILMN), a leading…

BiotechnologyIlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche ratchets up the pressure on Illumina; analytical view


If there is an axiom to describe Swiss drug major Roche (ROG: SIX), it is that what Roche wants, it gets,…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche presses on with takeover, despite further rejection by Illumina board


Swiss drug major Roche (ROG: SIX), admitting disappointment that the board of Illumina (Nasdaq: ILMN)…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Elan cashes in 76% chunk of its Alkermes stake for $381 million; Roche updates on Illumina bid


Ireland-based Elan Corp (NYSE: ELN) revealed yesterday that it has raised around $381 million in net…

AlkermesElanElan Drug TechnologiesFinancialIlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche has options beyond Illumina


Speaking at the companys annual meeting, Swiss drug maj'or Roche (ROG: SIX) chairman Franz Humer said:…

FinancialIlluminaMergers & AcquisitionsPharmaceuticalRoche

Illumina fails in patent litigation with LadaTech


USA-based Illumina (Nasdaq: ILMN) says that a federal jury in Wilmington, Delaware, found that certain…

IlluminaLadaTechLegalNorth AmericaPatentsPharmaceuticalRoche

Roche extends Illumina takeover deadline


Roche has extended its $5.7 billion hostile takeover offer for genetic sequencing specialist Illumina…

HomeIlluminaMergers & AcquisitionsPharmaceuticalRoche

Illumina board says Roche hostile bid “grossly inadequate”


Having thoroughly reviewed Swiss drug and diagnostics major Roche’s (ROG: SIX) hostile takeover…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Illumina implements “poison pill” with regard to Roche bid


Responding to Swiss drug major Roche’s (ROG: SIX) hostile takeover over offer of $44.50 per share…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Roche makes $5.7 billion hostile bid for Illumina


Swiss drugs and diagnostic major Roche (ROG: SIX) announced this morning that it is proposing to acquire…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top